<?xml version='1.0' encoding='utf-8'?>
<document id="22335429"><sentence text="Predicting drug candidate victims of drug-drug interactions, using microdosing." /><sentence text="The aim of this crossover human male volunteer study was to investigate the utility of microdosing in the investigation of drug-drug interactions" /><sentence text="" /><sentence text="A mixture of midazolam, tolbutamide, caffeine and fexofenadine were administered as a microdose (25 μg each) before and after administration of a combined pharmacological dose of ketoconazole (400 mg) and fluvoxamine (100 mg) to inhibit P-glycoprotein and metabolism by cytochrome P450 (CYP) 1A2, CYP3A4 and CYP2C9"><entity charOffset="13-22" id="DDI-PubMed.22335429.s4.e0" text="midazolam" /><entity charOffset="24-35" id="DDI-PubMed.22335429.s4.e1" text="tolbutamide" /><entity charOffset="37-45" id="DDI-PubMed.22335429.s4.e2" text="caffeine" /><entity charOffset="50-62" id="DDI-PubMed.22335429.s4.e3" text="fexofenadine" /><entity charOffset="179-191" id="DDI-PubMed.22335429.s4.e4" text="ketoconazole" /><entity charOffset="205-216" id="DDI-PubMed.22335429.s4.e5" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e0" e2="DDI-PubMed.22335429.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e0" e2="DDI-PubMed.22335429.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e0" e2="DDI-PubMed.22335429.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e0" e2="DDI-PubMed.22335429.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e0" e2="DDI-PubMed.22335429.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e0" e2="DDI-PubMed.22335429.s4.e5" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e1" e2="DDI-PubMed.22335429.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e1" e2="DDI-PubMed.22335429.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e1" e2="DDI-PubMed.22335429.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e1" e2="DDI-PubMed.22335429.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e1" e2="DDI-PubMed.22335429.s4.e5" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e2" e2="DDI-PubMed.22335429.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e2" e2="DDI-PubMed.22335429.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e2" e2="DDI-PubMed.22335429.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e2" e2="DDI-PubMed.22335429.s4.e5" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e3" e2="DDI-PubMed.22335429.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e3" e2="DDI-PubMed.22335429.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e3" e2="DDI-PubMed.22335429.s4.e5" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e4" e2="DDI-PubMed.22335429.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22335429.s4.e4" e2="DDI-PubMed.22335429.s4.e5" /></sentence><sentence text="" /><sentence text="When administered alone, pharmacokinetics for all four microdosed compounds scaled well with those reported for therapeutic doses and with previously performed microdose studies" /><sentence text=" The pharmacokinetics of each compound administered as a microdose were significantly altered after the administration of ketoconazole and fluvoxamine, showing statistically significant (p &lt; 0"><entity charOffset="122-134" id="DDI-PubMed.22335429.s7.e0" text="ketoconazole" /><entity charOffset="139-150" id="DDI-PubMed.22335429.s7.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.22335429.s7.e0" e2="DDI-PubMed.22335429.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22335429.s7.e0" e2="DDI-PubMed.22335429.s7.e1" /></sentence><sentence text="01) 12" /><sentence text="8-, 8" /><sentence text="1- and 3" /><sentence text="2-fold increases in the area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) for midazolam, caffeine and fexofenadine, respectively"><entity charOffset="111-120" id="DDI-PubMed.22335429.s11.e0" text="midazolam" /><entity charOffset="122-130" id="DDI-PubMed.22335429.s11.e1" text="caffeine" /><entity charOffset="135-147" id="DDI-PubMed.22335429.s11.e2" text="fexofenadine" /><pair ddi="false" e1="DDI-PubMed.22335429.s11.e0" e2="DDI-PubMed.22335429.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22335429.s11.e0" e2="DDI-PubMed.22335429.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22335429.s11.e0" e2="DDI-PubMed.22335429.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22335429.s11.e1" e2="DDI-PubMed.22335429.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22335429.s11.e1" e2="DDI-PubMed.22335429.s11.e2" /></sentence><sentence text=" A 1" /><sentence text="8-fold increase (not statistically significant) in AUC(∞) was observed for tolbutamide"><entity charOffset="75-86" id="DDI-PubMed.22335429.s13.e0" text="tolbutamide" /></sentence><sentence text=" The changes in pharmacokinetics mediated by ketoconazole and fluvoxamine were quantitatively consistent with previously reported, non-microdose, drug-drug interaction data from studies including the same compounds"><entity charOffset="45-57" id="DDI-PubMed.22335429.s14.e0" text="ketoconazole" /><entity charOffset="62-73" id="DDI-PubMed.22335429.s14.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.22335429.s14.e0" e2="DDI-PubMed.22335429.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22335429.s14.e0" e2="DDI-PubMed.22335429.s14.e1" /></sentence><sentence text="" /><sentence text="The initial data reported here demonstrate the utility of microdosing to investigate the risk of development drugs being victims of drug-drug interactions" /><sentence text="" /></document>